Q32 Bio (QTTB) Stock Price, News & Analysis

Company Overview

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Key Stats

• Today's Range: $14.75 to $15.95
• 50-Day Range: $5.18 to $21.38
• 52-Week Range: $1.57 to $23.57
• Volume: 1.32 million shs
• Average Volume: 2.45 million shs
• Market Capitalization: $255.25 million
• P/E Ratio: 8.79
• Dividend Yield: N/A
• Price Target: $22.33
• Consensus Rating: Moderate Buy

Q32 Bio Stock Analysis - MarketRank™

Q32 Bio scored higher than 95% of companies evaluated by MarketBeat, and ranked 21st out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Q32 Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Q32 Bio has a consensus price target of $22.33, representing about 48.4% upside from its current price of $15.05.

Amount of Analyst Coverage

Q32 Bio has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Q32 Bio are expected to grow in the coming year, from ($1.87) to ($1.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Q32 Bio is 5.66, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.11.

Price to Earnings Ratio vs. Sector

The P/E ratio of Q32 Bio is 5.66, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.24.

Price to Book Value per Share Ratio

Q32 Bio has a P/B Ratio of 4.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.09% of the float of Q32 Bio has been sold short.

Short Interest Ratio / Days to Cover

Q32 Bio has a short interest ratio ("days to cover") of 1.61, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Q32 Bio has recently decreased by 25.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Q32 Bio does not currently pay a dividend.

Dividend Growth

Q32 Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.40

News Sentiment

Q32 Bio has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Q32 Bio this week, compared to 2 articles on an average week.

Search Interest

Only 12 people have searched for QTTB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Q32 Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 4.7 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Q32 Bio in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $30,000,000.00 in company stock, which represents 11.7533% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Q32 Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $30,000,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

34.46% of the stock of Q32 Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

31.32% of the stock of Q32 Bio is held by institutions.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 7/17/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:QTTB
• Previous Symbol: NASDAQ:QTTB
• CIK: 1661998
• Web: www.homologymedicines.com
• Phone: 781-301-7277
• Fax: N/A
• Employees: 39
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Q32 Bio: $22.33
• High Price Target: $40.00
• Low Price Target: $13.00
• Potential Upside/Downside: +48.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.66
• Trailing P/E Ratio: 5.66
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $29.82 million
• Net Margins: N/A
• Pretax Margin: 61.86%
• Return on Equity: 149.23%
• Return on Assets: 34.50%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 5.36
• Quick Ratio: 5.36

Sales & Book Value

• Annual Sales: $53.74 million
• Price / Sales: 4.75
• Cash Flow: $1.45 per share
• Price / Cash Flow: 10.35
• Book Value: $3.41 per share
• Price / Book: 4.41

Miscellaneous

• Outstanding Shares: 16,960,000
• Free Float: 11,113,000
• Market Cap: $255.25 million
• Optionable: N/A
• Beta: 0.24